Literature DB >> 3972828

Branchpoint for heme alkylation and metabolite formation in the oxidation of arylacetylenes by cytochrome P-450.

P R Ortiz de Montellano, E A Komives.   

Abstract

Phenylacetylene and biphenylacetylene are oxidized by cytochrome P-450 to the corresponding arylacetic acids. The acetylenic hydrogen shifts to the adjacent carbon and one atom of molecular oxygen is incorporated into the carboxylic acid group in these transformations, which are subject to a large kinetic isotope effect when the acetylenic hydrogen is replaced by deuterium. The same products and isotope effects are observed when the two arylacetylenes are oxidized by m-chloroperbenzoic acid rather than by the enzyme. In contrast, the inactivation of cytochrome P-450 that occurs during the oxidation of phenylacetylene is insensitive to deuterium substitution. The partition ratio between metabolite formation and enzyme inactivation consequently changes from 26 to 15 in going from phenylacetylene to the deuterated analogue. Metabolite formation therefore diverges from heme alkylation very early in the catalytic process.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3972828

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetylene.

Authors:  Hsia-lien Lin; Haoming Zhang; Matthew J Pratt-Hyatt; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2011-09-19       Impact factor: 3.922

2.  Heme and I.

Authors:  Paul R Ortiz de Montellano
Journal:  J Biol Chem       Date:  2015-07-20       Impact factor: 5.157

3.  Catalytic control of enzymatic fluorine specificity.

Authors:  Amy M Weeks; Michelle C Y Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-12       Impact factor: 11.205

Review 4.  Acetylenes: cytochrome P450 oxidation and mechanism-based enzyme inactivation.

Authors:  Paul R Ortiz de Montellano
Journal:  Drug Metab Rev       Date:  2019-07-07       Impact factor: 4.518

5.  Heme Modification Contributes to the Mechanism-Based Inactivation of Human Cytochrome P450 2J2 by Two Terminal Acetylenic Compounds.

Authors:  Hsia-Lien Lin; Haoming Zhang; Vyvyca J Walker; Jaime D'Agostino; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2017-07-11       Impact factor: 3.922

6.  Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts.

Authors:  Chitra Sridar; Cesar Kenaan; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2012-08-30       Impact factor: 3.922

7.  Covalent modification of Thr302 in cytochrome P450 2B1 by the mechanism-based inactivator 4-tert-butylphenylacetylene.

Authors:  Hsia-lien Lin; Haoming Zhang; Monica Jushchyshyn; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2010-03-03       Impact factor: 4.030

8.  Mechanism-based inactivation of CYP2B1 and its F-helix mutant by two tert-butyl acetylenic compounds: covalent modification of prosthetic heme versus apoprotein.

Authors:  Hsia-Lien Lin; Haoming Zhang; Kathleen R Noon; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2009-08-21       Impact factor: 4.030

9.  Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6.

Authors:  Ute M Kent; Hsia-Lien Lin; Danielle E Mills; Kelly A Regal; Paul F Hollenberg
Journal:  Chem Res Toxicol       Date:  2006-02       Impact factor: 3.739

10.  Chemical proteomic probes for profiling cytochrome p450 activities and drug interactions in vivo.

Authors:  Aaron T Wright; Benjamin F Cravatt
Journal:  Chem Biol       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.